Stuart R. Weiss

TL;DR: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis.

TL;DR: In this article, the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis were studied.

TL;DR: Adding ezetimibe to ongoing statin therapy led to substantial additional reduction in LDL cholesterol levels, facilitating attainment of NCEP goals and offers a new therapeutic option for patients receiving statins who require further reduction in cholesterol levels.

TL;DR: Atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.

TL;DR: Total serum triglyceride levels decreased in a dose-dependent manner, reductions in the 20-mg and 80-mg groups were statistically significant and atorvastatin did not cause a redistribution of triglycerides but consistently lowered triglycerides in all lipoprotein fractions.